AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04423055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel contraceptive implant
Description: Place etonogestrel contraceptive implant.
Study NCT01640782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin
Description: * Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~* Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~* Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~* Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles.
Study NCT01640782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin, 5-Fluorouracil
Description: * Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~* 5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations.
Study NCT02586623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa capsules
Description: 100, 200 or 300 mg
Study NCT02586623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Droxidopa capsules
Description: 100, 200 or 300 mg
Study NCT02586623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study NCT04485546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cenegermin-bkbj
Description: Cenegermin-bkbj ophthalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks
Study NCT03077542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haploidentical stem cell transplant
Description: haploidentical stem cell transplant
Study NCT03077542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: conditioning regimen
Study NCT03077542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: conditioning regimen
Study NCT03077542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: conditioning regimen
Study NCT03077542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: conditioning regimen
Study NCT03077542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: conditioning regimen
Study NCT03077542 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim
Description: A haploidentical relative donor will receive filgrastim (G-CSF) 10 to 16 µg/kg/d subcutaneously or intravenously for up to 6 days with apheresis collections of peripheral blood hematopoietic progenitor cells (PBPC) after the 5th day (and after the 6th day if required).
Study NCT01333293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injections
Description: subcutaneous injections
Study NCT01333293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injections
Description: subcutaneous injections
Study NCT02911974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acquire EUS Biopsy Device
Description: 1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
Study NCT02911974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Expect EUS Aspiration Needle
Description: 1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
Study NCT01943812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol and progeterone
Description: Estradiol and progesterone
Study NCT01943812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol and progeterone
Description: Estradiol and progesterone
Study NCT03318380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Ultrasound Imaging
Description: Undergo CEUS
Study NCT00775099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
Study NCT02558075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoodLifters Sessions
Description: This program consists of 15 different sessions with a different topic for each session. These sessions will occur once a week for 15 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
Study NCT01998659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Px-102
Description: Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg
Study NCT01998659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral drinking solution
Study NCT04536818 — intervention group
Intervention type: PROCEDURE
Intervention: Laparotomy
Description: Exploratory laparotomy.
Study NCT02673827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
Study NCT06063980 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional sinus lift surgery
Description: After graft reflection, sinus membrane is separated from bone or oral mucosa and then bone graft is inserted in between the two structures.
Study NCT06063980 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Two-stage-sinus-lift procedure
Description: Procedure is performed in two stages with the purpose of stage one to separate the oral mucosa from the sinus membrane using a small amount of bone graft and stage two as actual sinus augmentation, which is performed similar to that of conventional sinus lift procedure.
Study NCT02524366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Urinary Sphincter
Study NCT02524366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Urinary Sphincter
Study NCT04048616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: whey protein isolate
Description: one 15-25 gm (based on body weight) protein packet three times a day with each meal
Study NCT04048616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: potassium bicarbonate (KHCO3)
Description: two 13.5 mmol capsules three times a day with each meal
Study NCT04048616 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: identical placebo capsule
Study NCT04048616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: microcrystalline cellulose
Description: identical placebo capsule
Study NCT04048616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin powder
Description: isocaloric placebo powder
Study NCT04048616 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin powder
Description: isocaloric placebo powder
Study NCT01997060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Study NCT00423501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sc weekly
Study NCT00423501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 20mg sc weekly
Study NCT00423501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc every 2 weeks
Study NCT00423501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 5mg sc weekly
Study NCT00423501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc weekly
Study NCT00423501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 20mg sc every 2 weeks
Study NCT03458039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person CETA
Description: The Common Elements Treatment Approach (CETA) is a transdiagnostic, multi-problem intervention designed to address adult and youth trauma, depression, anxiety, safety, and substance use. It is comprised of a small set of common elements found to be efficacious and prevalent across a range of EBTs to treat common mental health problems. CETA was designed to be flexible in the elements utilized, their order, and their dose (number of sessions) to allow counselors to address heterogeneity, comorbidity, and symptom fluctuations in and across clients. Treatment typically consists of 6 to 12 weekly, approximately 60-minute sessions delivered by lay workers.
Study NCT03458039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone CETA
Description: For adaptation of the CETA manual for telephone delivery, the Applied Mental Health Research (AMHR) Group at Johns Hopkins University (JHU) reviewed evidence-based telehealth strategies and recommendations, telehealth ethical and legal guidelines, and clinical recommendations from telehealth providers. In addition, local TTTs in multiple contexts reviewed telehealth modifications and provided input that was incorporated into the final T-CETA manual used in this study. No changes were made to the structure, duration, and dose of CETA sessions, treatment components, or measurement-based clinical decision-making processes. Telehealth modifications, additions, and strategies were incorporated throughout the manual in delineated telehealth boxes. This way, the original manual was maintained outside of the telehealth boxes, allowing for clear identification and training of telehealth modifications for both new and existing CETA counselors.
Study NCT03458039 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care treatments for mental and behavioral health problems among AYA. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some AYA receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control participants if it has been found to be safe and effective
Study NCT02175927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: antisecretory drug of each quadruple therapy
Study NCT02175927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: antisecretory drug of each quadruple therapy
Study NCT02175927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium Citrate
Description: one component of each quadruple therapy
Study NCT02175927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium Citrate
Description: one component of each quadruple therapy
Study NCT02175927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: antibiotic of each quadruple therapy
Study NCT00775099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using Badimon Chamber
Study NCT02175927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: antibiotic of each quadruple therapy
Study NCT02175927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: antibiotic of high dose amoxicillin based quadruple therapy
Study NCT02175927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: antibiotic of classical quadruple therapy
Study NCT03887013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Description: Trimetazidine is given as 20mg every time and three times per day (Tid) or 20mg every time and two times per day (when renal function is declined).
Study NCT02490449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Administration of drug after or before diet
Study NCT02490449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexlansoprazole MR
Description: Administration of drug after or before diet
Study NCT00628550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: One dose of vasopressin (0.8 units/kg) intravenously rescue as the second vasopressor medication.
Study NCT00628550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
Study NCT02090816 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery of liver and lung
Description: Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
Study NCT04073316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 MG
Description: Rivaroxaban intake, 20mg/day
Study NCT04073316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin intake, with target INR range between 2 and 3
Study NCT03240887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Group Connection
Description: Faculty advisors at each participating high school are trained to run the program and teach a daily leadership course to peer leaders. Eleventh and twelfth-grade peer leaders who participate in the daily leadership development class facilitate outreach sessions with their assigned group of ninth graders. PGC can be offered in either a half-year (semester) or full-year format. In either format, a minimum of 18, 45-minute outreach sessions are expected to be offered to PGC participants during the course of their ninth-grade year. Outreaches are created to facilitate the transition to high school and encourage students to attend school, set goals for themselves, and make healthy decisions.
Study NCT04019912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training plus music
Description: GaitTrainer3 is a platform that integrates gait training via a treadmill and RAS. The device is indeed equipped with an instrumented deck that issues acoustic cues to determine the exact tempo and rhythm during gait training and visual real-time biofeedback to prompt patients to follow their gait pattern. In fact, the device provides online feedback, including step length, speed, and symmetry, to encourage patient progress and monitor patient performance. Patient footfalls were compared in real-time to the desired footfalls step by step and documented in a histogram.
Study NCT04019912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Gait Training
Description: The traditional training will be provided by a conventional treadmill.
Study NCT01045564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK influenza virus H5N1 vaccine 1557484A
Description: Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
Study NCT02910466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on Albumin-corrected Serum Calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
Study NCT03899298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amniotic and Umbilical Cord Tissue Procedure
Description: Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition. Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
Study NCT01526707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled steroid
Description: inhaled budesonide for 7 days
Study NCT01407510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: Application of the investigational product on the affected skin areas
Study NCT06653920 — intervention group
Intervention type: OTHER
Intervention: Chiropractic
Description: SM used by the practitioner was the chiropractic side posture pisiform contact push move with a P-A thrust isolated to the lumbosacral joints and applied to the side of primary back and/or leg pain. Patients presenting with spondylolisthesis received a side posture distraction type maneuver instead of a P-A thrust. As pain began to subside during subsequent visits patients were transitioned to bilateral application of SM, rather than continuing treatment only on the side of back pain or radiculopathy.
Study NCT06653920 — intervention group
Intervention type: OTHER
Intervention: Exercise
Description: Core spine stretch and strength training throughout the course of care.
Study NCT06653920 — intervention group
Intervention type: OTHER
Intervention: Cryotherapy
Description: Therefore, during each treatment session when patients reported pain they received pretreatment with cryotherapy using a reusable ice pack (Polar Ice, Pelton/Shepherd Industries, Stockton, California) wrapped in 2 layers of headrest paper, but otherwise applied directly to the skin vertically along the lumbosacral spine, for 5 minutes.
Study NCT03627871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Majority Norm
Description: Participants receive information about exercise norms that apply to the majority of the population but are given no information about trends in this norm.
Study NCT06653920 — intervention group
Intervention type: DEVICE
Intervention: Spinalator
Description: When patients no longer reported leg pain, spinalator intersegmental traction at \~10 lb/F, while the patient was lying supine with an ice pack between the traction table and the lumbar spine, was permitted as a pretreatment to side posture lumbar manipulation.
Study NCT01222962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurartesim
Description: Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.
Study NCT03305926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CVR programme
Description: Programme in a CVR centre involving 20 sessions of reconditioning to effort, 3 times per week for roughly 7 weeks, as well as 14 sessions of therapeutic education in groups.
Study NCT03305926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connected CVR programme
Description: First week in the CVR centre with 3 sessions combining reconditioning to effort, individual interviews and targeted therapeutic education, so as to define the objectives and methods of the connected CVR at home for the 6 following weeks.
Study NCT02467101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corticosteroid/Saline
Description: Corticosteroid/Saline~Two groups were defined: group A and group B.~* Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head~* Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.~Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.~Each patient will be injected on half-head.
Study NCT00645333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0752, Docetaxel, Pegfilgrastim
Description: MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
Study NCT02559388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Study NCT02559388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills